Covidien (COV) Pharma Spin-Off Mallinckrodt Applies for NYSE Listing
Tweet Send to a FriendGet Alerts COV Hot Sheet
Up)
Trade COV Now!
Covidien (NYSE: COV) announced that Mallinckrodt plc intends to apply to list its ordinary shares on the New York Stock Exchange (NYSE) to trade under the symbol MNK.
As previously announced, Covidien plans to spin off its Pharmaceuticals business into Mallinckrodt, a stand-alone company, a process expected to be completed in mid-2013.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
As previously announced, Covidien plans to spin off its Pharmaceuticals business into Mallinckrodt, a stand-alone company, a process expected to be completed in mid-2013.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Covidien Board of Directors Approves Separation of Pharmaceuticals Business and Declares Dividend of Mallinckrodt Ordinary Shares
- Merck (MRK) Says Efficacy Not Achieved in Preladenant Phase 3s; Will Discontinue
- Covidien’s Technology Platform to Diagnose Early Lung Cancer Part of New Guidelines of American College of Chest Physicians
Create E-mail Alert Related Categories
Corporate News
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
